Association between statin use and rates of structural and functional loss in glaucoma.

BACKGROUND/AIMS: To evaluate the association between statin use and rates of standard automated perimetry (SAP) and retinal nerve fibre layer (RNFL) change in patients with glaucoma and glaucoma suspects.

METHODS

This retrospective cohort study included subjects from the Duke Glaucoma Registry with primary open-angle glaucoma and glaucoma suspects. Subjects were assigned to groups according to history of statin use. Rates of change in SAP mean deviation (MD) and spectral-domain optical coherence tomography (SD OCT) RNFL thickness over time were estimated using linear mixed models and compared in the statin versus control groups. The effect of duration of statin use was also assessed. Patients with glaucoma versus suspects were analysed separately. Analyses were adjusted for potential confounding factors of age, gender, race, intraocular pressure and follow-up time.

RESULTS

The study included 10 049 SAP tests and 14 198 SD OCT tests from 3007 eyes (1978 patients) followed for an average of 4.7±2.0 years. Of these, 775 subjects (1179 eyes) had a history of statin use. No difference in rates of change was seen between the statin versus control groups for MD (-0.07±0.16 dB/year vs -0.07±0.15 dB/year; p=0.873, respectively) or RNFL thickness (-0.70±0.60 µm/year vs -0.70±0.61 µm/year; p=0.923, respectively). Multivariable models controlling for potential confounders showed no significant association between duration of statin use and rates of MD or RNFL thickness change.

CONCLUSIONS

We did not find a statistically significant association between statin use or duration of statin use and rates of structural and functional change in those with glaucoma or glaucoma suspects.